Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Farxiga is expected to have such a strong influence on the market due to the impressive results
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
To focus on providing safer burn treatments for women and armed forces
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Study achieves primary endpoint of radiographic progression-free survival
Subscribe To Our Newsletter & Stay Updated
